Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura

Haematologica

Volumn 99, Issue 4, 2014, Pages

  Grillberger, Rana ^a   Casina, Veronica C ^b   Turecek, Peter L ^a   Long Zheng, X ^b   Rottensteiner, Hanspeter ^a   Scheiflinger, Friedrich ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ADAMTS13 antibodies; Epitope mapping; Linear epitopes; Thrombotic thrombocytopenic purpura

Indexed keywords

AUTOANTIBODY; EPITOPE; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G AUTOANTIBODY; PROTEIN G; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; IMMUNOGLOBULIN G;

ANTIBODY AFFINITY; CASE REPORT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; LETTER; SOMATIC HYPERMUTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; WESTERN BLOTTING; BLOOD; IMMUNOLOGY; NORMAL HUMAN;

ADAM PROTEINS; AUTOANTIBODIES; EPITOPE MAPPING; EPITOPES; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGLOBULIN G; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84897405459     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.100685     Document Type: Letter

References (19)

1. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262-7.
2. Klaus C, Plaimauer B, Studt JD, Dorner F, Lammle B, Mannucci PM, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103(12):4514-9.
3. Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, Van Mourik JA, et al. Amino acid regions 572-579 and 657-666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost. 2006;96(3):295-301.
4. Zheng XL, Wu HM, Shang D, Falls E, Skipwith CG, Cataland SR, et al. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010;95(9):1555-62.
5. Yamaguchi Y, Moriki T, Igari A, Nakagawa T, Wada H, Matsumoto M, et al. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Thromb Res. 2011;128(2):169-73.
6. Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, and Luken BM. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood. 2010;115(8):1640-9.
7. Pos W, Sorvillo N, Fijnheer R, Feys HB, Kaijen PH, Vidarsson G, et al. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica. 2011;96(11):1670-7.
8. Jian C, Xiao J, Gong L, Skipwith CG, Jin SY, Kwaan HC, et al. Gainof-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2012;119(16):3836-43.
9. Luken BM, Kaijen PH, Turenhout EA, Kremer Hovinga JA, Van Mourik JA, Fijnheer R, et al. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2006; 4(11):2355-64.
10. Shukla NM, Salunke DB, Balakrishna R, Mutz CA, Malladi SS, and David SA. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS One. 2012;7(8):e43612.
11. Igari A, Nakagawa T, Moriki T, Yamaguchi Y, Matsumoto M, Fujimura Y, et al. Identification of epitopes on ADAMTS13 recognized by a panel of monoclonal antibodies with functional or nonfunctional effects on catalytic activity. Thromb Res. 2012;130(3):e79-e83.
12. Crawley JT, de Groot R, Xiang Y, Luken BM, and Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011;118(12):3212-21.
13. Moriki T, Maruyama IN, Igari A, Ikeda Y, and Murata M. Identification of ADAMTS13 peptide sequences binding to von Willebrand factor. Biochem Biophys Res Commun. 2010;391(1):783-8.
14. Yang R, Cui Z, Hellmark T, Segelmark M, Zhao MH, and Wang HY. Natural anti-GBM antibodies from normal human sera recognize alpha3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clin Immunol. 2007;124(2):207-12.
15. Ueki A, Isozaki Y, Tomokuni A, Hatayama T, Ueki H, Kusaka M, et al. Intramolecular epitope spreading among anti-caspase-8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals. Clin Exp Immunol. 2002;129(3):556-61.
16. Mietzner B, Tsuiji M, Scheid J, Velinzon K, Tiller T, Abraham K, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA. 2008;105(28):9727-32.
17. Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123(4):1773-83.
18. Coppo P, Busson M, Veyradier A, Wynckel A, Poullin P, Azoulay E, et al. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost. 2010;8(4):856-9.
19. Olson SW, Arbogast CB, Baker TP, Owshalimpur D, Oliver DK, Abbott KC, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol. 2011;22(10):1946-52.